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Abstract
Background: Evaluating experiences of volunteers in an HIV vaccine trial will be useful for the conduct of future
trials. The purpose of this study among volunteers who participated in a phase I/II HIV vaccine trial in Dar es
Salaam, Tanzania was to assess what characterized their experiences during the trial.
Methods: We conducted four focus group discussions with 35 out of the 60 individuals (women and men) after
the five scheduled vaccinations. An interpretive description approach was applied to data analysis.
Results: As a result of the trial interventions, both men and women gained confidence in their own abilities to
have safer, less risky sexual behaviour. The participants experienced the trial as a way of accessing free [insured]
medical services. Most of the men said they had gone from self-medication to professional medical consultation.
Despite these benefits, the participants faced various challenges during the trial. Such challenges included mistrust
of the trial shown by health care providers who were not connected to the trial and discouragement from friends,
colleagues and family members who questioned the safety of the trial. However, they managed to cope with
these doubts by using both personal and trial related interventions.
Conclusion: We found that during the phase I/II HIV vaccine trial, participants had both the opportunities and the
ability to cope with the doubts from the surrounding community. Follow up visits enhanced the opportunities and
individuals’ abilities to cope with the doubts during the trial. Understanding this discourse may be useful for the
trial implementers when designing future trials.
Trials Registration: ISRCTN: ISRCTN90053831
Pan African Clinical Trials Registry (PACTR): ATMR2009040001075080
Background
Participants who enrol in HIV vaccine trials may face
diverse problems, including social harm which refers to
a negative trial-related experience by a study participant
which manifest in psychological, social or physical ways
[1]. Previous studies in phases I and II HIV vaccine
trials at different sites have shown evidence of trial par-
ticipants experiencing social harm. These include nega-
tive reactions from friends, family, co-workers or
disturbance in relationships [2-4]. Also, during the
efficacy trials, participants reported concerns by family
and friends associated with the perception that volun-
teers were HIV-infected or were at risk of HIV infection
[5,6]. In a systematic review, disturbance in personal
relationships was the main type of social harm in all
phases [1]. Other studies address positive social out-
comes of participating in HIV vaccine trials such as less
risky sexual behaviour among trial participants [4,7].
These studies are, however, from countries where sev-
eral HIV vaccine trials are being conducted. Little is
known about experiences of volunteers in low income
countries where few HIV vaccine trials have been con-
ducted [8].
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conducting phase I/II HIV vaccine trials [8]. One of
such trials is HIV Vaccine Immunogenicity Study
(HIVIS03), which was conducted among healthy volun-
teers in Dar es Salaam. Evaluation of immunogenicity
test results from the volunteers indicated higher and
broader immune responses [9]. It is felt that evaluating
social and behavioural experiences of the volunteers
during the trial may be a useful complement to immu-
nogenicity findings. The social behavioural results may
also be important in addressing various concerns at
community level. Therefore, the purpose of this study
was to evaluate what characterized experiences of volun-
teers during the HIVIS03 trial.
The interpretive description (ID) approach [10] was
used to analyze the result data. By using ID, we provide
contextual understanding to guide future research on
people. ID generates new insights on what may charac-
terize the experiences of individuals who enrol in HIV
vaccine trials in a similar context.
Methods
Study setting
The clinical part of the HIVIS03 was conducted at a
t r i a ls i t el o c a t e da tM u h i m b i l iN a t i o n a lH o s p i t a l
(MNH), Dar es Salaam, Tanzania. The trial was a colla-
boration between, among others, the Muhimbili Univer-
sity of Health and Allied Sciences (MUHAS) in
Tanzania and the Karolinska Institutet in Sweden. This
qualitative socio-behavioural evaluation study was con-
ducted at the clinical trial site.
Study population
The HIVIS03 project enrolled 60 volunteers (45 men
and 15 women) in the Phase I/II HIV vaccine trial. All
volunteers were recruited from the police force and all
of them were police officers [11,12]. Before the vaccina-
tions, potential volunteers attended a series of work-
shops and discussions with trial staff [12]. During these
workshops, all participants were given written docu-
ments with details about the trial design, and the trial
team encouraged them to share such documents with
their relatives, friends and colleagues. Among other
issues, the focus of these workshops was to discuss the
criteria for enrolment in the HIV vaccine trial. The cri-
teria included: be between 18 and 40 years old; be will-
i n gt os t a yi nt h es t u d yf o rt h es t a t e dp e r i o do f2 4
months; women must not be pregnant and must use an
effective contraceptive method for the duration of the
trial; agree to HIV testing and adhere to condom use to
prevent HIV acquisition, sexually transmitted infections
and to avoid pregnancy. In the workshops, the trial
team strived to provide precise and accurate information
and answers to questions to the potential volunteers.
The implementation of the trial adhered to study pro-
tocol. After enrolling in the trial, a total of 16 study vis-
its were spread over the trial period. During these visits,
volunteers were screened through clinical history and
examination [13]. Follow-up visits at the trial site were
carried in accordance with the AIDS Vaccine Literacy
Toolkit [14]. Volunteers received clinical care at the trial
clinic for minor ailments, while for other ailments, they
were referred to specialized facilities and such services
were paid for by the trial insurance company. Before
participation in the trial, participants were paying out of
pocket and reimbursed by their employer in order to
access medical services from public or private health
care facilities.
At regular intervals during the trial, workshops were
held to update the volunteers on the progress of the trial.
During these workshops, volunteers were reminded
about the importance of adhering to safer sex practices
because the vaccine used in the trial was yet to be proven
to protect against HIV transmission. The likelihood of
possible false positive HIV diagnostic test results with
standard HIV diagnostic antibody assays resulting from
the candidate vaccines was impressed upon the volun-
teers. It was also emphasized repeatedly that the candi-
date vaccine products used in humans could never cause
HIV infection in the vaccinees. Volunteers were advised
that in case they required an HIV test in the future, the
trial clinic would help them to have an HIV DNA PCR
test done in the study laboratory which would distinguish
between vaccine-induced antibodies and the presence of
H I VD N Ad u et ot r u eH I Vi n f e c t i o n .T h u s ,d u r i n gt h e
trial, volunteers were advised not to have an HIV test
outside the trial clinic. In each workshop, volunteers
were invited to discuss various trial related issues.
Study design
This was a qualitative evaluation study, nested in the
HIVIS03 trial to evaluate social issues as stated in the
project protocol. The qualitative method was chosen
because it explores the shared perspectives and range of
issues as expressed in the participants’ own words better
than the quantitative method.
Recruitment
We made two announcements about this study during
the regular workshops with the HIVIS03 volunteers.
Firstly, we told them that they would be invited to focus
group discussions to share their experiences during the
trial after scheduled vaccinations, and we informed
them that participation was voluntary. The second
announcement was made in a workshop two months
before some of the volunteers completed the last vacci-
nation (MVA Boost) informing them that only those
who had not participated in an earlier interview [15]
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volunteers who were eligible and willing to participate
in the study were asked to confirm their participation
by ticking their names in a pre-prepared list. All eligible
potential participants who were in the workshop ticked
their names on the list. Before the study, the first author
grouped the potential participants according to gender
and marital status. The number of participants per
group followed the recommended size for focus group
of 6-12 participants [16]. Thereafter, each participant
was sent a letter of invitation to participate in the study
on a specified date and time. On arrival at the study
site, each participant completed a registration form with
personal socio-demographic characteristics and was
assigned a tag number (1-11) for anonymity during the
discussion. An assistant [not the trial staff] assisted with
the registration process.
Sampling procedure and framework
The study included a purposive sample of volunteers
who participated in HIVIS03 trial, who were still in
contact with the trial team, and were available during
the study. Of the 60 trial participants, 17 participants
were excluded from the sampling because they had
shared their experiences in a previous interview [15].
Eight participants were eligible for the study but were
not available during the last workshop when confirma-
tion to participate in the discussions took place; they
w e r en o t e dt h a tt h e yw e r en o ti nD a re sS a l a a ma n d
they would be out of Dar es Salaam at the time of the
planned study. The rest confirmed their participation
and were invited to participate in the study (Figure 1).
Data collection
We collected data between March and April 2009, after
completion of two years of HIV vaccine trial study. Data
was collected in a spacious room with chairs arranged
in semi-circle for face-to-face interaction. We used
focus group discussions (FGDs) because FGDs are typi-
cally designed to elicit normative feelings, responses,
experiences, or world-views [17], and to meet time and
resource constrains. Participants were arranged in
. Enrolled volunteers (45 men, 15 
women).
Eligible participants for 
FGD (35 men, 8 women).
Participants excluded because they 
took part in interviews before (10 
men, 7 women). Of these, 8 men and 
4 women respectively completed all 
the 5 vaccinations.
Study participants
Participants registered for FGDs (28 
men, 7 women)- Of these, 26 men 
and one woman had received all 5 
vaccinations (DNA/placebo). The 
rest had received 3-4 vaccinations.
Not accessible for FGD 
(7 men, 1 woman) – Of 
these, three men had all 
5 vaccinations. The rest 
had received 3-4 
vaccinations.
men, 7
4 wom
the 5 v
Figure 1 Sampling framework.
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English, translated into Kiswahili and translated back
into English, was used to moderate the discussion. Each
group was re-introduced to the purpose of the study,
and given rules such as showing respect for each other,
turning off mobile phones and the importance of identi-
fying each other by number throughout the discussion.
They were also reminded to share both positive and
negative opinions, and that the information generated
would be treated as group opinions or views. One ques-
tion was asked: “Can you tell us your opinion on
changes that occurred during the vaccination period?”
This question was followed by probing questions.
Throughout the discussions, participants identified and
addressed each other by numbers tagged on their tops/
shirts. The first author moderated all the discussions
and a note taker [two academic colleagues interchange-
ably] took notes. The discussion was audio-recorded.
Participants were served with a bottle of water during
the discussion; soft drinks and snacks were served at the
end of the session. They were also reimbursed in Tanza-
nian shillings [equivalent to $ 20 USD for transport to
and from the study site]. The discussion sessions lasted
between 79 and 115 minutes.
Data analysis
Interpretive description (ID) approach informed by prin-
ciples of thematic content analysis was followed when
analyzing the data [10,18]. Analysis began immediately
after each FGD. The first author listened to the audio-
recorded material and compared the identity of each
participant with the note-taker’s summary for consis-
tency. This process allowed the author to understand
the clarity of voices in the audio-recording and define
key phrases that were specific to certain people in the
s e t t i n go ft h es t u d y[ 1 9 ]O n ea s s i s t a n tt r a n s c r i b e dt h e
audio-recorded material; another translated the tran-
scripts from Kiswahili into English. For consistency,
both versions were read and checked by two authors,
EAMT and TWK who speak Kiswahili and English. Dif-
ferences in language interpretation were discussed and
both Kiswahili and English quotes were re-checked for
consistency. EAMT matched each transcript with the
note-takers’ summary [key point of the speech and iden-
tity of the speaker] and the registration form. This
matching enabled the author to merge individual tag
number [identity], marital status and group number in
each transcript for quotations.
In the process of interpreting the findings, EAMT and
TWK coded each transcript paragraph by paragraph.
The manual coding carried the participant identity [sex,
tag number, and marital status] and group number as
text locators. The process of coding was inductive in
nature. By using an inductive approach, we sought to
explore the data and to identify emerging findings. The
initial phrase consisted of identifying codes and giving
them a distinct code. Further, EAMT and AK tested the
coding by trying different angles of vision, while appre-
ciating the implications of each option for grouping and
reconstructing the categories. The initial inductive cod-
ing was aimed at primarily identifying descriptive codes.
This was followed by the process of bringing together
all codes which were related. Following this process,
categories were formed from the codes (Example given
in Figure 2). In the process of moving from codes to
categories, an attempt at interpretive analysis was
included. Data within the data set were systematically
compared to ensure no key finding was left out. Follow-
ing the identification of categories, these were brought
together into two themes. The themes emerged from
the underlying meaning of the categories while they also
stayed close to application potentials of interpretive
description [20]. Our findings were cross-checked with
trial participants in order to increase trustworthiness.
Participants consented to the interpretation made.
Ethical considerations
The HIVIS03 trial project to which this evaluation study
is affiliated was approved by the National Ethics Com-
mittee at the National Institute for Medical Research
(NIMR) which offered a letter with reference number
NIMR/HQ/R.8a/Vol.IX/410. A thorough process of
obtaining informed consent and satisfying eligibility cri-
teria was a prerequisite for enrolment in the trial. Before
the discussions, potential participants gave verbal con-
sent after re-describing the purpose of the study. They
were reminded about the issues of confidentiality and
their rights as participants. They were also asked to
adhere to the principles of shared confidentiality
[between the group members and the researcher], and
Table 1 Participants
Group Participants’ characteristics Number of participants
1 Men (married [5] and unmarried [4]), mean age 27 years old 9
2 Men (all unmarried men), mean age 28 years old 11
3 Women (married [2] and unmarried [5]), mean age 27 years old 7
4 Men (all married), mean age 36 years 8
Total 35
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cussion. They all gave their consent and participated
fully in the study.
Results
Participants
Of the 35 participants, seven were women and the age
ranged between 23 and 42 years. A total of 13 men were
married and 15 were single. Two and five women were
married and single respectively (Table 1). Although we
did not explore about the participants HIV risk factors
such as homosexuality or heterosexuality, those who
were in sexual relationships indicated that they had part-
ners or spouses from the opposite sex. Twenty seven par-
ticipants had four years of secondary education and
above. The rest had seven years of primary education.
Themes
Two major themes emerged from the analysis, ‘Embra-
cing benefits of participating in an HIV vaccine trial’
and ‘Encountering and handling mistrust about an HIV
vaccine trial’. Within each theme, four categories were
formed (Table 2).
Embracing benefits of participating in an HIV vaccine trial
Reducing risky sexual behaviour
Participation in the HIV vaccine trial was experienced as
beneficial to the participants’ sexual life. Before the trial,
the participants confessed that they were poorly
informed about HIV transmission. They stated that the
information in the trial enabled them to change their
behaviour and practice safer sex. In other words, they
became optimistic about safer sexual lifestyles. The male
participants said they decreased the number of sexual
partners as a result of the information from the trial.
They asserted that although risky sexual behaviour was
part of their daily lives, they managed to adopt safer
sexual practices due to the information in the trial.
Other participants asserted that they changed their
behaviour at different points along the trial. Some of
Text
I joined because of my 
courage; You have power 
and not afraid; You 
sacrifice yourself when 
you fight for your 
country; Jesus died on 
the cross to save others, 
so I sacrifice myself too
Text
The vaccine will help 
other people; I have 
decided to sacrifice 
myself to rescue the 
world; Our main task is 
to protect lives of people 
and their properties; Our 
work is to sacrifice for 
others
Codes
Being courageous
Role model
Codes
Helping others
Save the world
Unselfishness
Category
Pride of fulfilment 
and self-respect
Figure 2 Example of coding process.
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Page 5 of 13them changed after a negative HIV test; others were
encouraged to maintain positive behaviour after the sec-
ond and the third DNA injections, something which is
exemplified by the following quote:
“For my part, I changed the first day I tested. I think
that the test made me change, and the results were
clean. Truly, I gained courage, and I was very
happy... That has helped me a lot to change my
behaviour.” (Man 3, married, Group 1)
Besides changing risky sexual behaviour, participants
also reported that they advised others to practice safer sex:
“Those seminars helped us a lot because from the
first vaccination, we were told that wearing a con-
dom is really important. That one helped because
some of us had multiple sexual partners... It [semi-
nar] has helped and strengthened me a lot. I mean, I
do not have strange things [risk behaviour].... To a
large extent, I was able to advise my friends.” (Man
6, married, Group 1)
Women stated that they benefited from the correct
information on how to avoid pregnancy and sexually
transmitted infections. In addition, the participants
believed that the routine HIV testing in the trial con-
tributed to the behaviour change:
“You find testing for HIV is voluntary, but when you
are in the research [trial], that voluntarism is not
there. So it compels you to protect yourself in any
way. Now you find yourself automatically changing
your behaviour. It means you are forced to live a
certain lifestyle...” (Man 3, unmarried, Group 2)
Acceptability of condom use emerged as an engaging
topic for discussion among the participants, who
claimed that the information in the trial helped them to
understand the value of using a condom to prevent
infections and pregnancy. Although other participants
were confused whether to consistently use condoms
with their stable sexual partners, most of them declared
that regular seminars strengthened their trust of con-
dom use, and some admitted they were now being more
careful during intercourse even though they were wear-
ing a condom.
Overcoming fear of HIV testing
The participants said that the fear associated with test-
ing for HIV status had been eliminated by the trial
interventions. Participants declared that they had more
confidence in HIV testing compared to their colleagues
who were not in the trial:
“After joining this research, I have gained confidence
which I did not have before. That is confidence to
test for HIV status, readiness to take whatever test
results, something that would be very difficult for
other people.” (Man 3, unmarried, Group 2)
Also, participants added that during the trial they felt
more confident because of the results from HIV testing
and reflections on their health status:
“When you look at your [my] own health, and it is
progressing well and telling a person that, ‘I checked
my health status yesterday and I have no HIV infec-
tion and my results are here’, he/she understands
even though I am enrolled in the HIV vaccine trial.”
(Woman 7, married, Group 3)
Most of the participants said that the issue of HIV
testing did not trouble them after enrolling in the trial.
They emphasized that they were very careful to protect
themselves against HIV transmission.
Privilege of complete medical examination
Enrolling in the HIV vaccine trial was perceived as a
privilege in accessing medical services. For instance, par-
ticipants experienced the trial as a way of being able to
have voluntary medical check-ups. Through these
check-ups, most of them said that they learnt about
their general health status. They appreciated this oppor-
tunity because before the trial most of them did not
bother to seek professional medical advice. In the trial,
they adopted the habit of checking their health status
even when they were not sick. The group participants
Table 2 Themes and categories
Themes Categories
Embracing benefits of participating in an HIV vaccine trial Reducing risky sexual behaviour
Overcoming fear of HIV testing
Encountering and handling mistrust in an HIV vaccine trial Privilege of complete medical check-ups
Changed to better health-seeking behaviour
Dealing with attitude of mistrust of non-trial health care providers
Confronting discouragement from colleagues
Convincing the family
Pride of fulfilment and self-respect
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“Even me, I benefited... The first benefit we got is
check up; I know my health status on what is going
on...”
According to the participants’ past experiences, medi-
cal check-up was not a priority. They emphasized that
they only sought medical check-up when it was neces-
sary. Thus, courage and hope after being properly exam-
ined and receiving medical treatment emerged as an
important benefit of enrolling in the HIV vaccine trial:
“Everything you checked, you were told by the doc-
tor, that you were okay ... when you went out, you
got a relief that you did not have any problem. You
see, because if a person had kidney problems, he
was given treatment. Therefore, that gave us courage
and hope...” (Man 6, married, Group 4)
Changed to better health-seeking behaviour
Before enrolling in the trial, the participants said that
they used self- medication. During the trial, however,
they accessed professional services through counselling,
consultation; proper treatment and regular follow-up.
They learnt about the importance of adhering to profes-
sional advice throughout:
“Being in the research has influenced me to leave the
doctor free to check my health status and decide
which medicine to use.” (Man 7, married, Group 1)
They said that the tradition of self-prescription was
enhanced by perceived lack of trust in doctors:
“Previously, I feared to consult the doctors, and I
didn’t like it. I perceived them differently. When I
fell sick, I bought my Panadol and took it. That is
it...” (Man 3, married, Group 4)
Possible causes of hesitations to consult doctors in
time of illnesses were aired by other participants. They
felt that doctors investigated more than what the clients
expected from them:
“First of all you may go to consult a doctor because
of ‘malaria’, but through his professional expertise,
he may ask you to give blood from this site [pointing
at a common site where blood is taken for tests like
HIV]. I think you will even escape to pick the medi-
cations, and you will not return for the test results....
This is because of the existing problem [HIV].”
(Man 4, married, Group 4)
Overall, participants experienced the trial follow-ups
as a way of accessing professional health services which
promoted confidence in their HIV status, general health
status, and in their relationship with the trial team.
Encountering and handling mistrust about the trial
Dealing with the attitude of mistrust of non-trial health
care providers
Despite the opportunities in the trial, the participants
faced challenges from health care providers who were
not connected to the trial. The participants were unex-
pectedly forced to interact with health care providers
who were not informed or poorly informed about the
HIV vaccine trial. Interaction with these providers was
difficult. Although they were surprised by the attitude of
mistrust among these providers, they managed to use
active and passive strategies to defend their decision to
enrol in the trial. They shared experiences and how they
reacted when they interacted with medical doctors [doc-
tors who were not connected to the trial] facilitating an
HIV and AIDS workshop at their workplace as exempli-
fied in the quote:
“This program [HIV vaccine trial] is in the police
force, but I feel very sorry for those who joined in
because they will be seriously affected’ [said a doc-
tor]. After hearing that, I neither responded nor
showed up that, I was among the trial participants! I
took him as he was.” (Man 3, unmarried, Group 2)
This attitude of mistrust was not just among medical
specialists. The participants also noted opposition to the
HIV vaccine trial from other health care providers.
Another participant shared his encounter with a labora-
tory technologist:
“I can add on that ... it is the same people; those
whom we call health experts and who are not in the
trial. Somebody who is a laboratory technician...
Intentionally, you could see him/her mobilizing peo-
ple and being the main speaker, misleading them
about the trial... Being part of it [trial volunteer], you
keep quiet; pretending not knowing what he is talk-
ing about ...” (Man 4, unmarried, Group 2).
The participants were confused when faced with mis-
trust among medical doctors over the trial, especially
when they sought medical consultation outside the trial
clinic. Despite their expectations that all health care
providers would know about the trial, surprisingly, they
realised that most of them did not know or were poorly
informed. Under such circumstances, the participants
stated that they were confused:
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something [HIV vaccine trial], and he/she comments
‘he!’, in your heart you feel: ‘Does it mean that I am
lost?’... I met a specialist, the one they call an ortho-
paedic surgeon. Just by seeing my documents [HIV
vaccine trial volunteer], he was shocked in such a
way that shocked me too ... then he called his nurse;
she also looked at the documents in brief, and then
they looked at each other. Things like those, we just
say, let us go ahead...” (Man 9, unmarried, Group 2)
Older married men encountered a similar situation
a n dt h e yw e r ea l s oc o n f u s e db yn e g a t i v ec o m m e n t s
from health care providers. One participant expressed
his feelings after interacting with a medical doctor who
was poorly informed about the trial, but he passively
managed the situation. He said:
“This thing [vaccine trial] is impossible. Personally, I
k n o wt h es i d ee f f e c t s ,t h o s eo fy o uw h oj o i n e da r e
insane’ [A doctor commented]. These are truly
health care experts of whom we expect to be cham-
pion in such issues, but they are the main barriers...
we just volunteered because of courage... If I die, it
is okay, and if I survive ‘Insha’Allah’,y o us e e ?B u t
we were disturbed.” (Man 6, married, Group 4)
Generally, the participants expressed disappointment
following the reactions of the health care providers out-
side the trial team.
Confronting discouragement from colleagues
Regarding existing relationships and daily interactions at
the workplace, participants’ enrolment in the HIV vac-
cine trial was something that distinguished them from
their peers. The participants stated that their time spent
at the workplace became less enjoyable during the trial.
They said they met discouragement from colleagues in
the form of jokes, and rumours that the vaccine trial
was not safe. They also noted that the discouragement
was frequently accompanied by negative opinions
towards them. Sometimes they felt discriminated
against, humiliated and upset when colleagues and
friends commented negatively about them. They either
actively educated them, confirmed that they were HIV
negative or passively kept quiet to maintain a peaceful
situation. One participant said:
“At our workplace, people joked a lot: ‘You have
been transplanted with HIV’ [colleagues said]. Some-
times it discouraged us; you find yourself arguing
with people ...You find somebody scorning you; you
just ignore him/her. At most I would call him/her
and educate even if he/she did not understand.”
(Man 6, married, Group 1)
Other participants experienced disturbance when col-
leagues who were not in the trial stigmatized them in
front of other people. One man said a colleague pointed
his finger at him in a canteen in front of more than
twenty people, ‘This is the one who has been trans-
planted with HIV virus.’ [He shouted]. He said the situa-
tion forced him to defend that he was only taking part
in the HIV vaccine research, not transplanted with HIV,
but they [civilians] continued to question him. To clear
the doubt he disclosed that he had re-tested and he had
confirmed that he was not infected with HIV. Also,
other participants added that they had repeated HIV
testing in different places to confirm that the vaccine
was not infectious:
“I have talked to that one [colleague] for a long time
to clarify the truth, and I told him that besides the
tests at the trial site, I have been re-tested to see
whether I am infected or otherwise. I have tested in
different places where they do not even know me in
order to gain more confidence.” (Man 7, married,
Group 1)
Commonly, participants faced difficulty in clarifying
the information about the vaccine trial to people
because of the novelty of it among community mem-
bers. They thought they could give up, but they realized
that they should continue to educate those who were
ready to pay attention:
“We are facing difficulties in educating a person who
does not know it [HIV vaccine trial] and make him/
her understand. Although in the place where we live,
there are people who talk nonsense in front of
others, we need to accept them, they are our collea-
gues, and we cannot avoid them.” (Man 4, unmar-
ried, Group 1)
Although the participants stated that the workshops
strengthened their knowledge about the vaccine and its
safety, they still experienced difficulties in delivering the
information to the community. Women felt that the
friends believed that the HIV vaccine trial had negative
consequences on their reproductive health:
“And another person suspected that I could not give
birth because of the vaccine. I mean for example at
the workplace, aah, truly God helped us. We have
come a long way and now we are breathing... They
s a wu sa sp e o p l ew h oa r ei n f e c t e dw i t ht h ev i r u s . . .
waiting to die and that confused us.” (Woman 1,
married, Group 3)
Other participants recognized that their colleagues
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they passed, inferring that they were already infected.
Although they realized that the negative opinions they
came across were linked to mistrust of the HIV vaccine
in the community, they felt traumatized with such opi-
nions especially during illness episodes. One participant
said her boss disappointed at her bedside in the hospital
to which she had been admitted for a surgical procedure
[non-trial-related]. She said that her boss offended her
by saying, ‘those people [researchers] are selling you,
and they benefit because of you [said the boss]’. She felt
disappointed and placed everything on faith. She lamen-
ted:
“Given that I was sick, then hearing such words! The
only answer I had was: ‘If dying is for human beings,
living is also for human beings... In the beginning,
you take those words, but often they are painful!”
(Woman 4, unmarried, Group 3)
Another woman related her experience during illness
and how she passively reacted while interacting with
colleagues:
“I was suffering from typhoid illness...When I went
to the office they [colleagues] told me that, ‘You
know it is that vaccine that brings such illness’.I
remained quiet and asked myself, ‘don’tt h e ye v e n
care that I am sick? To tell the truth those words
were painful...” (Woman 6, unmarried, Group 3)
The participants continued to struggle against people
who were discouraging them. Although, they realized
that some were labelling them as ‘people who are con-
fused by enrolling in the trial’, they believed such nega-
tive views could not change their mind set because of
the correct information they had received on the trial.
Convincing the family
The common comfort zone, the family where supportive
networks are established, turned out to be a discomfort
zone during the trial. Several participants noted mistrust
of the trial among members of the family when they
said they were participating. Discomfort often emerged
when close family members, such as parents, sexual
partners, and blood relatives, demonstrated mistrust of
the vaccine safety. Under such situations, participants
were forced to carefully deal with the doubts to main-
tain existing relationships. For instance, some men
reported that their wives were distressed by the com-
ments from the surrounding communities that their
husbands were taking part in a harmful study. Under
such a circumstance, they tirelessly educated them.
Other participants admitted that their pre-understanding
about their families was helpful to deal with the
situation. Some of them opted to share the information
with their intimate friends, but not their mothers
because of perceived different levels of understanding:
“I tried hard to explain to my lover but when it
came to the other side, the side of the parents... I
didn’t tell my mother this issue because I knew it
w o u l dt a k et i m ef o rh e rt ou n d e r s t a n d . . . ” (Man 3,
unmarried, Group 2)
On the contrary, those who shared their enrolment in
the trial with relatives, they felt abandoned. However,
they passively kept quiet and continued with the trial.
One man shared his experience:
“I tried to explain [about the trial] to my relatives.
Truly, all of them threw me out of the line [discour-
aged me]... So, I am alone; they find its okay. When
I phoned and told them that I have fever, they say:
‘You wait, go ahead!’ [The relatives warned]. So
those are their current responses. Now even if I have
mild-fever, I don’t call them.” (Man 7, unmarried,
Group 2)
O t h e rp a r t i c i p a n t si nt h eg r o u ps e n s e dt h a tt h er e a c -
tion from the family members was more negative than
that of friends. For example, they noted that some par-
ents were shocked after realizing that, without their
knowledge, their sons and daughters were participating
in the HIV vaccine trial. One woman shared how her
father was shocked and how he forced her to re-test
for HIV to rule out any negative consequences of tak-
ing the vaccine. After the first two DNAs, she said her
father pretended to organize a family event that every
family member had to accompany him on the AIDS
day, December 1
st,t oh a v ea nH I Vt e s t .T h u s ,t h e
whole family went with him to the HIV testing centre
[not at the trial site]. On the contrary, some of the
participants experienced comfort from their families.
To some extent, they sensed good relationships. Never-
theless, one participant pointed out that the relation-
ship was maintained because the vaccine had no
v i s i b l es i d ee f f e c t s .
Therefore, some participants had positive interaction
with their families during the trial while others did not.
On top of looking healthier, they relied on their indivi-
dual decision that pushed them to enrol and eventually
stayed on until the end of the trial. The following sec-
tion highlights these individual motives.
Pride of fulfilment and self-respect
Participants felt they had made an important decision
and believed that self-sacrifice, self-courage and faith in
the vaccine trial were important to accomplish their
contribution in the HIV vaccine development.
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realized that individual decision was crucial:
“It [discouragement] is there. Others were pressing
me until I decided to tell them, ‘I have decided to
sacrifice myself; I have already sacrificed to rescue
this world. If it is a vaccine, then it will help other
people... Jesus died on the cross to save others. So, I
sacrifice myself too ...” (Man 7, married, Group 4)
Through body gestures, other group participants indi-
cated that this was an experience they could identify
with. Most of them reflected on a similar situation when
they interacted with colleagues and friends. The partici-
pants referred to their core role as an opportunity to
protect people and their properties. Thus through parti-
cipation in the trial, they believed that they would also
protect people’s health. They emphasized that taking
part in the trial was a courageous act to save the nation
from the HIV calamity:
“You have power and are not afraid. You sacrifice
yourself when you fight for your country ...”
(Woman 6, unmarried, Group 3)
Individual decision was the basis of volunteering for
the HIV vaccine trial. Thus, to a large extent, the parti-
cipants managed to deal with the doubts in the trial
because of this decision. They also felt they were able
to ignore negative comments from others because of
confidence they had in the trial from the start, and
asserted that participation in the trial was a personal
decision sometimes driven by the death of a relative
from AIDS:
“To me it is my own decision. When I decide to do
something and I see it is beneficial to me, I just do
it ...we have lost two relatives [AIDS-related death]
from our family. Truly, it hurts me so much. So,
when I heard about this vaccine trial, I decided
straight away. I mean, nothing can change me.”
(Man 6, married, Group 1).
Also, they felt confident because of regular contacts
with the trial team. They said they experienced warmth
and friendliness during such contacts. They boasted that
they knew more facts about HIV and vaccine than their
colleagues because they attended the workshops.
Discussion
This socio-behavioural evaluation study shows that dur-
ing the phase I/II HIV vaccine trial in Dar es Salaam,
the participants’ lives were characterized with both posi-
tive and negative experiences. The trial interventions
promoted individual gains in terms of safer sex, habit of
having HIV tests when ever need arose, access to free
(insured) medical services during the trial period and
establishment of good relationship with the trial health
care and research team. In spite of these opportunities,
the participants faced several challenges when they
interacted with people who were not connected to the
HIV vaccine trial research. The volunteers actively or
passively managed to cope with the doubts, stigmatisa-
tion, and misinformation throughout the trial period.
They demonstrated pride of fulfilment and self-respect
when committing to their participation in the trial.
T h ee x p e r i e n c eo fc h a n g ef r o mr i s k yt os a f e rs e x u a l
behaviour of the trial participants implies individual gain
through the trial interventions. The regular monitoring
of HIV status and counselling may have greatly contrib-
uted to the positive change in behaviour. However, the
big challenge is whether or not the volunteers sustain
the safer sexual practices in absence of the trial inter-
ventions. A previous study on this trial population
showed that participants’ willingness to participate in an
HIV vaccine trial was associated with perceived risk of
getting HIV infection [11]. Elsewhere, participants in
efficacy trials engaged in risky behaviours consistently
over the 6-, 12- and 18-months follow up visits [21], but
a decrease in risky behaviour in phases II [7] and III
trials has been documented from other studies [22-24].
However, it is not predictable which trend the post-
HIVIS03 volunteers will follow given the differences in
context and type of the HIV vaccine trial they were
enrolled in and the environment they will continue to
be in. While the volunteers in the HIVIS03 were gener-
ally perceived to be at a low risk of becoming HIV
infected at the time of enrolment, the findings in this
sub study show that several of them perceived them-
selves at risk. In Tanzania, risky sexual practices and not
having regular HIV tests overrides the need for the
national advocacy on behaviour change, counselling and
voluntary HIV testing among other appropriate inter-
ventions [25]. The current findings however, signify the
contribution of the trial interventions to the behaviour
changes; changes that seem glowing according to the
participants’ own expressions. While the appreciation by
the volunteers for the HIV tests and general medical
check-ups received during the trial contradicts with the
earlier findings from the similar population [12], we
believe that access to precise information, health ser-
vices and the availability of medical insurance in the
trial are the core sources of the appreciation. The
experience of volunteers gained through the trial inter-
ventions supports the findings of others [3,7,23].
The mistrust of significant others on the HIV vaccine
trial is not surprising. In the similar population, signifi-
cant others were potential barriers [12] and the main
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Page 10 of 13reason for declining to enrol in the HIV vaccine trial
[13]. What is now becoming serious is the attitude of
m i s t r u s to ft h eh e a l t hc a r ep r o v i d e r sw h o ,b e c a u s eo f
their professional background, would be expected to
support the medical interventions. This situation
demands a wider approach for dissemination of infor-
mation on HIV vaccine trials, particularly to specific
groups of stakeholders in the communities from which
trial participants are drawn. The Good Participatory
Practice (GPP) guidelines for biomedical HIV prevention
trials provide a list of stakeholders which include trial
participants; families of trial participants; community
members residing within or in the surroundings; the
research catchment area; people living with AIDS or
affected by HIV; advocates and activists; non-govern-
mental organisations; community based organisations;
religious leaders; opinion leaders; media; government
bodies; national and local health care authorities; service
providers; trial funders; trial sponsors and trial imple-
menters [26]. Also, Allen and Lau provide a model to
prevent social impact related to HIV vaccine trial parti-
cipation [27]. Although the mistrust of significant others
(not medically trained) about HIV vaccine trials has
been documented in previous studies [2,3,5], the utilisa-
tion of the above guidelines will substantially increase
the dissemination of trial information.
The strategies employed to cope with the doubts in
the HIVIS 03 trial may have been greatly enhanced by
the routine follow-ups, services and the precise informa-
tion about the phase I/II trial. However, some volunteers
underwent HIV tests outside the trial clinic because of
the confusing rumours from the surrounding commu-
nity. The negative reactions of the colleagues towards
them reflect the misconceptions about the vaccine in
the surrounding community. The participants’ response
regarding how they coped signifies that human beings
are passive recipients of social environment influences
to which they simply respond [28]. While interacting
with non-trial health care providers, participants simply
behaved neutrally implying that they avoided arguing
with the ‘perceived knowledgeable’ people. This could
be based on the way in which they relate to actions
[28]. Nevertheless, at some points they were over-
whelmed beyond their ability to accommodate the
instructions from the trial staff. Here, the participants
were obliged to defend the trial safety, not only by pro-
viding correct information about the trial, but also by
quoting evidence from outside the trial site. Neverthe-
less, the participants maintained trust in the trial until
the end, mostly because of the trial interventions.
Methodological considerations
This qualitative study was planned to cover the first part
of the vaccination period, stretching from the first to the
fifth vaccination. The second part of the trial was
unblinded and volunteers told whether they had
received an active vaccine or placebo. We note that
unblinding occurred after data collection for this study,
and all volunteers who had received all the five active
vaccine products exhibited vaccine-induced HIV-1 sero-
positivity [29]. It would be of great interest to have an
idea on how those who tested positive for HIV antibo-
dies but were HIV DNA negative behaved or responded
socially, and how their significant others reacted (for
those who got informed). However, the experience
gained from the first part of the study is broader and
useful for future trial implementers. Understanding of
socio-behavioural reactions of the volunteers and their
significant others after unblinding will perhaps increase
our knowledge as regards phase I/II HIV vaccine trial
participation.
Although we cannot generalize these findings beyond
the studied sample of volunteers, the information
obtained sounds crucial when it comes to designing
HIV vaccine trials in similar contexts. The use of quali-
tative approach allowed us to explore a scientific area
that has not been well investigated before. Even though
the use of FGDs could have limited the discussion to
sensitive sexual matters [30], they provide findings
which can often be used as a basis for actions [31].
Similarly, by using ID approach, data analysis is oriented
towards the development of useful findings for practice
[32]. Intentionally, in this evaluation, we excluded the
participants who shared their experiences in interview
right after the third DNA or placebo injections. This
allowed the researchers to gain collective experiences
from those who had no chance to share them. The
moderator of the FGDs being part of the trial team may
have influenced the participants not to disclose negative
experiences gained at the trial clinic. However, we
believe that the trial staff, with whom the participants
had regular contact may have taken care of any immedi-
ate concerns they may have had.
In terms of reflexivity, participants demonstrated trust
in the moderator [EAMT] of FGDs possibly because of
her presence in the workshops before and during the
trial. In spite of introducing her role as a social scientist
in the trial project, the participants perceived her as a
representative from the trial team. While this seemingly
did not pose a problem, it is impossible to say whether
this misinformation led to a censuring of some content.
However, since both positive and negative views were
expressed on most topics discussed, we see this effect as
minimal.
Implications
In future trials, it is crucial to conduct quantitative
longitudinal studies to monitor possible post-trial
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this study can be minimized by timely dissemination of
the trial information to the respective stakeholders.
Involving past trial volunteers in the sensitization or
recruitment meetings of prospective future vaccinees
may provide valuable evidence on trial safety to the
surrounding community. Regular follow-ups can build
and sustain good rapport between the volunteers and
the trial staff. In particular, when the trial volunteers
encounter doubts from outside the trial, they should
continue to have access to immediate support or
someone to turn to for reassurance. The proposed
guidelines of good participatory practice in conducting
biomedical trials need to be implemented and moni-
tored according to the trial context. The most impor-
tant group to start with would be the health care
providers in the respective community; they are the
most trustful people when it comes to health-related
information. Also, the findings suggest that volunteers
who decide to enrol in the HIV vaccine trial do show
a degree of independent thinking when resisting dis-
couraging messages.
Conclusions
The article presents an evaluation of the volunteers’
experience in an HIV vaccine trial in Dar es salaam,
Tanzania. The benefits experienced by the trial partici-
pants are connected to the interventions in the trial
such as regular follow-ups, medical check-ups, counsel-
ling and regular interaction with the trial team. Such
benefits are however tempered by the challenges from
the surrounding community. The issue of mistrust of
the trial from health care providers who were not con-
nected to the trial is more serious than the discourage-
ment from the colleagues. However, personal
commitment and trial-related interventions were impor-
tant for the participants to stay on in the trial.
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